Applying contemporary immunology to elucidate heterologous effects of infant vaccines and to better inform maternal-infant immunization practices

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Wilson, Christopher B ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Heterologous immunity; Infant immunity; Maternal immunization; Trained immunity

Indexed keywords

BCG VACCINE; INFLUENZA VACCINE; MEASLES VACCINE;

ADAPTIVE IMMUNITY; ENVIRONMENTAL EXPOSURE; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; INFANT IMMUNITY; INFANT IMMUNIZATION; INNATE IMMUNITY; MATERNAL IMMUNIZATION; NEWBORN MORTALITY; NOTE; PREMATURE LABOR; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; VACCINATION;

EID: 84926670626     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00064     Document Type: Note

References (22)

1. Mackaness GB. Cellular resistance to infection. J Exp Med (1962) 116:381-406. doi: 10.1084/jem.116.3.381
2. Blanden RV, Lefford MJ, Mackaness GB. The host response to Calmette-Guerin bacillus infection in mice. J Exp Med (1969) 129(5):1079-107. doi:10.1084/jem.129.5.1079
3. Sjogren HO, Ankerst J. Effect of BCG and allogeneic tumor cells on adenovirus type 12 tumorigenesis in mice. Nature (1969) 221(5183):863-4. doi:10.1038/221863a0
4. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol (2014) 5:446. doi:10.3389/fimmu.2014.00446
5. MacGillivray DM, Kollmann TR. The role of environmental factors in modulating immune responses in early life. Front Immunol (2014) 5:434. doi:10.3389/fimmu.2014.00434
6. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol (2014) 15(10):895-9. doi:10.1038/ni.2961
7. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA (2012) 109(43):17537-42. doi:10.1073/pnas.1202870109
8. Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective: experimental models and immunological mechanisms. Trans R Soc Trop Med Hyg (2015) 109(1):46-51. doi:10.1093/trstmh/tru197
9. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol (2002) 168(2):919-25. doi:10.4049/jimmunol.168.2.919
10. Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity (2014) 41(3):478-92. doi:10.1016/j.immuni.2014.08.009
11. Chu HY, Englund JA. Maternal immunization. Clin Infect Dis (2014) 59(4):560-8. doi:10.1093/cid/ciu327
12. Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med (2014) 371(24):2340. doi:10.1056/NEJMc1412050
13. Gans HA, Maldonado YA. Loss of passively acquired maternal antibodies in highly vaccinated populations: an emerging need to define the ontogeny of infant immune responses. J Infect Dis (2013) 208(1):1-3. doi:10.1093/infdis/jit144
14. Martins C, Garly ML, Bale C, Rodrigues A, Njie-Jobe J, Benn CS, et al. Measles virus antibody responses in children randomly assigned to receive standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age. J Infect Dis (2014) 210(5):693-700. doi:10.1093/infdis/jiu117
15. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol (2014) 15(8):707-16. doi:10.1038/ni.2939
16. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell (2014) 158(3):481-91. doi:10.1016/j.cell.2014.06.022
17. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature (2014) 509(7498):55-62. doi:10.1038/nature13036
18. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 501(7467):439-43. doi:10.1038/nature12442
19. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, et al. Proof of principle for epitope-focused vaccine design. Nature (2014) 507(7491):201-6. doi:10.1038/nature12966
20. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 340(6136):1113-7. doi:10.1126/science.1234914
21. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics (2011) 127(5):e1161-8. doi:10.1542/peds.2010-1920
22. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity (2012) 37(5):771-83. doi:10.1016/j.immuni.2012.10.014